6637-29-2

Basic information

• Product Name: 2-(phenoxymethyl)-1H-benzimidazole hydrochloride
• Synonyms: 2-(phenoxymethyl)-1H-benzimidazole hydrochloride;1H-BenziMidazole, 2-(phenoxyMethyl)-;1H-Benzoimidazole, 2-phenoxymethyl-;2-Phenoxymethyl-1H-benzoimidazole;2-(phenoxymethyl)-1H-benzo[d]imidazole
• CAS NO: 6637-29-2
• Molecular Formula: C₁₄H₁₂N₂O
• Molecular Weight: 224.26
• Mol File: 6637-29-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 467.7 °C at 760 mmHg
• Flash Point: 167.2 °C
• Appearance: /
• Density: 1.247 g/cm³
• Vapor Pressure: 1.78E-08mmHg at 25°C
• Refractive Index: 1.677
• CAS DataBase Reference: 2-(phenoxymethyl)-1H-benzimidazole hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(phenoxymethyl)-1H-benzimidazole hydrochloride(6637-29-2)
• EPA Substance Registry System: 2-(phenoxymethyl)-1H-benzimidazole hydrochloride(6637-29-2)

Safety Data

• Hazardous Substances Data: 6637-29-2(Hazardous Substances Data)

Usage

General Description

2-(phenoxymethyl)-1H-benzimidazole hydrochloride is a chemical compound that contains a benzimidazole ring and a phenoxymethyl group. It is commonly used as an anti-ulcer agent and is known for its potent anti-secretory and cytoprotective properties. 2-(phenoxymethyl)-1H-benzimidazole hydrochloride has been studied for its potential role in the treatment of peptic ulcers and gastroesophageal reflux disease. Its mechanism of action involves inhibiting the secretion of gastric acid and promoting the healing of damaged gastrointestinal mucosa. Additionally, it has shown promise in the management of other gastric and duodenal disorders. Overall, 2-(phenoxymethyl)-1H-benzimidazole hydrochloride is a pharmaceutical compound with therapeutic potential in the field of gastroenterology.

InChI:InChI=1/C14H12N2O/c1-2-6-11(7-3-1)17-10-14-15-12-8-4-5-9-13(12)16-14/h1-9H,10H2,(H,15,16)

Upstream product

• 40828-54-4 1H-benzimidazole-2-sulfonic acid 
• 122-59-8 2-phenoxyacetic acid 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 1039358-73-0 C₂₁H₂₅ClN₂O 
• 1039358-74-1 C₂₂H₂₇ClN₂O 
• 1039358-75-2 C₂₃H₂₉ClN₂O 
• 1039358-71-8 C₁₉H₂₁ClN₂O 
• 1039358-76-3 C₂₄H₃₁ClN₂O 
• 92756-20-2 C₂₁H₁₆N₂O₂ 
• 1039358-69-4 C₁₇H₁₇ClN₂O 
• 439574-26-2 C₂₁H₁₈N₂O₃S 
• 1039358-70-7 C₁₈H₁₉ClN₂O 
• 1039358-72-9 C₂₀H₂₃ClN₂O 
• 112055-57-9 C₁₇H₁₅N₃O 
• 1425336-52-2 1-(2-hydroxyphenyl)-3-(2-phenoxymethyl-1H-benzimidazol-1-yl)-1-propanone 
• 1425336-66-8 1-(2-hydroxy-5-methylphenyl)-3-(2-phenoxymethyl-1H-benzimidazol-1-yl)-1-propanone 
• 378766-45-1 1-isobutyl-2-(phenoxymethyl)-1H-benzimidazole 

Relevant articles and documents

Quantum mechanical and spectroscopic (FT-IR, FT-Raman, 1H NMR and UV) investigations of 2-(phenoxymethyl)benzimidazole

The optimized molecular structure, vibrational frequencies, corresponding vibrational assignments of 2-(phenoxymethyl)benzimidazole have been investigated experimentally and theoretically using Gaussian09 software package. The energy and oscillator streng

Synthesis and molecular structures of 1-hydroxyethyl-2-(p-substituted) phenoxymethyl benzimidazoles

Five novel 1-hydroxyethyl-2-(p-substituted) phenoxymethyl benzimidazoles were synthesized by a three-step route. Under microwave irradiation, the p-substituted phenols were firstly O-carboxymethylated to prepare the corresponding p-substituted phenoxymethyl acids, which then reacted with o-phenylendiamine to get the key intermediates 2-(p-substituted) phenoxymethyl benzimidazole. Finally, the solid-liquid phase transfer catalysis method, where tetrabutyl ammonium bromide (TBAB) was used as the catalyst, was applied to synthesize the target compounds c1-c5 by the N-hydroxyethylation reaction with 2-chloroethyl alcohol. The structures of the obtained compounds were well characterized and confirmed by elemental analysis, MS, IR, 1H NMR, 13C NMR and single-crystal X-ray diffraction analysis.

BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT

The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.